

# Biosimilar Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023

<https://marketpublishers.com/r/B8783BED1A1EN.html>

Date: April 2018

Pages: 172

Price: US\$ 1,999.00 (Single User License)

ID: B8783BED1A1EN

## Abstracts

The biosimilar market reached a value of US\$ 2.9 Billion in 2017. This market is currently being driven by a number of factors such as patent expires of blockbuster biological drugs, lower prices, rising prevalence of chronic diseases, and cost saving initiatives from governments and third party payers. Catalyzed by these factors, the market is further projected to reach US\$ 15.6 Billion by 2023, at a CAGR of around 30% during the next five years

Biosimilars, also known as follow-on biologics, refers to a biotherapeutic product which is highly similar to a reference biologic drug. It is produced using living organisms or cells and has a complex molecular structure. When the patent of a biologic drug expires, manufacturers resort to the approval from the regulatory authorities so as to start the production of biosimilars. For being labelled as a biosimilar, a biological drug should be proved similar in terms of quality, safety and efficacy. In comparison with generic drugs, biosimilars are expensive as their production process is more complex and requires higher investment in research and development.

Global Biosimilar Market Drivers/Constraints:

Over the years, the patents of several blockbuster biologic drugs have expired and a number of blockbuster drugs are further expected to lose patent protection in the coming years. This is expected to provide tremendous opportunities for biosimilar manufacturers in the near future.

Cost saving initiatives undertaken by governments and third-party payers have encouraged the use of biosimilars over branded biologics, thereby propelling the demand of biosimilars.

Some of the other factors bolstering the demand for biosimilars include cost-

effectiveness, rising prevalence of chronic diseases (such as autoimmune diseases and cancer) and growing geriatric population.

There are some factors hampering the growth of the biosimilars market. This includes negative perception from physicians, patent extensions, lower price differential compared to small molecule generics, etc.

#### Molecule insights:

On the basis of molecule, the market has been segmented as Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, etc. Currently, Infliximab dominates the market, holding the largest share.

#### Indication Insights:

Based on the indication, autoimmune diseases account for the majority of the total market share. Other major indications include oncology, diabetes, blood disorder, growth deficiency, female infertility, etc.

#### Manufacturing Insights:

Based on the type of manufacturing, the market is segregated into in-house manufacturing and contract manufacturing. Amongst these, in-house manufacturing accounts for the majority of the market share.

#### Regional Insights:

Region-wise, the market has been segmented into the United States, Germany, France, Italy, Spain, United Kingdom, Japan, India, South Korea and Others. Amongst these, Italy is the biggest market, accounting for the majority of the global biosimilar market.

#### Competitive Landscape:

The competitive landscape of the global biosimilar market has also been analysed. Some of the leading players operating in the market are:

Novartis

Pfizer

Teva

Celltrion  
Merck & Co  
Samsung Bioepis  
Eli Lilly  
Biocon  
Dr. Reddy's Laboratories  
Amgen  
Boehringer Ingelheim

This report provides a deep insight into the global biosimilars market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the biosimilars market in any manner.

#### Key Questions Answered in This Report:

How has the global biosimilars market performed so far and how will it perform in the coming years?

What are the key regional markets in the global biosimilar industry?

What are the major molecule types in the global biosimilar industry?

What are the various manufacturing types in the global biosimilar industry?

What are the various indications in the global biosimilar industry?

What are the price trends of biosimilars?

What are the various stages in the value chain of the global biosimilar industry?

What are the key driving factors and challenges in the global biosimilar industry?

What is the structure of the global biosimilar industry and who are the key players?

What is the degree of competition in the global biosimilar industry?

What are the key requirements for setting up a biosimilar manufacturing plant?

How are biosimilars manufactured?

What are the machinery requirements for setting up a biosimilar manufacturing plant?

What is the capital cost for setting up a biosimilar manufacturing plant?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 BIOSIMILARS MARKET – INTRODUCTION**

- 4.1 Overview
- 4.2 WHO and FDA Terminology on Biosimilars
- 4.3 Biosimilars and Generics
- 4.4 Biosimilars and Branded Biological Products

### **5 WHY ARE BIOSIMILARS SO LUCRATIVE?**

- 5.1 Patent Expiry of Blockbuster Biological Drugs
- 5.2 Significant Price Differential between Biosimilars and Innovator Drugs
- 5.3 Savings for the Government and Third Party Payers
- 5.4 Rising Prevalence of Lifestyle Diseases
- 5.5 Incentives for Prescribers, Pharmacists and Patients
- 5.6 Emergence of New Players in Europe and Emerging Markets
- 5.7 Increasing Product Differentiation as Manufacturers Tie-Up with Drug Delivery Device Companies

### **6 BIOSIMILAR RESEARCH, DEVELOPMENT AND MANUFACTURING**

- 6.1 Research and Development: Biosimilars vs. Innovator Drugs

## 6.2 Manufacturing: Biosimilars vs. Innovator Drugs

# 7 BIOSIMILARS MARKET

## 7.1 Market Overview

## 7.2 Historical Performance

## 7.3 Market Breakup by Segment

## 7.4 Market Breakup by Manufacturer Type

## 7.5 Market Breakup by Indication

## 7.6 Market Breakup by Region

## 7.7 Market Forecast

## 7.8 Biosimilar Patent Landscape

### 7.8.1 Patent Landscape in the US

### 7.8.2 Patent Landscape in Europe

### 7.8.3 Patent Landscape in Japan

## 7.9 SWOT Analysis

### 7.9.1 Strengths

### 7.9.2 Weaknesses

### 7.9.3 Opportunities

### 7.9.4 Threats

## 7.10 Value Chain Analysis

### 7.10.1 Characterizing the Existing Innovator Drug

### 7.10.2 Research and Development

#### 7.10.2.1 Characterization of Biosimilars

#### 7.10.2.2 Developing a Unique Cell Line

### 7.10.3 Product Development

#### 7.10.3.1 Pre-Testing

#### 7.10.3.2 Intermediary Clinical Testing (PK/PD)

#### 7.10.3.3 Confirmatory Clinical Phase-III

### 7.10.4 Final Product Formulation

### 7.10.5 Marketing and Distribution

## 7.11 Porter's Five Forces Analysis

### 7.11.1 Overview

### 7.11.2 Bargaining Power of Buyers

### 7.11.3 Bargaining Power of Suppliers

### 7.11.4 Degree of Competition

### 7.11.5 Threat of New Entrants

### 7.11.6 Threat of Substitutes

## 7.12 Price Analysis

- 7.12.1 Price Indicators
- 7.12.2 Price Trends
- 7.12.3 Margin Analysis

## **8 MARKET BREAKUP BY MOLECULE**

- 8.1 Infliximab
- 8.2 Insulin Glargine
- 8.3 Epoetin Alfa
- 8.4 Etanercept
- 8.5 Filgrastim
- 8.6 Somatropin
- 8.7 Rituximab
- 8.8 Follitropin Alfa

## **9 MARKET BREAKUP BY TYPE OF MANUFACTURING**

- 9.1 In-house Manufacturing
- 9.2 Contract Manufacturing

## **10 MARKET BREAKUP BY INDICATION**

- 10.1 Auto-Immune Diseases
- 10.2 Blood Disorder
- 10.3 Diabetes
- 10.4 Oncology
- 10.5 Growth Deficiency
- 10.6 Female Infertility

## **11 MARKET BREAKUP BY REGION**

- 11.1 Europe
  - 11.1.1 Market Performance
  - 11.1.2 Key Players and Biosimilars
  - 11.1.3 Market Breakup by Country
  - 11.1.4 Market Forecast
  - 11.1.5 Italy
    - 11.1.5.1 Market Performance
    - 11.1.5.2 Key Players and Biosimilars

- 11.1.5.3 Market Forecast
- 11.1.6 Germany
  - 11.1.6.1 Market Performance
  - 11.1.6.2 Key Players and Biosimilars
  - 11.1.6.3 Market Forecast
- 11.1.7 France
  - 11.1.7.1 Market Performance
  - 11.1.7.2 Key Players and Biosimilars
  - 11.1.7.3 Market Forecast
- 11.1.8 United Kingdom
  - 11.1.8.1 Market Performance
  - 11.1.8.2 Key Players and Biosimilars
  - 11.1.8.3 Market Forecast
- 11.1.9 Spain
  - 11.1.9.1 Market Performance
  - 11.1.9.2 Key Players and Biosimilars
  - 11.1.9.3 Market Forecast
- 11.1.10 Rest of Europe
  - 11.1.10.1 Market Performance
  - 11.1.10.2 Market Forecast
- 11.2 United States
  - 11.2.1 Current Market Trends
  - 11.2.2 Key Players and Biosimilars
  - 11.2.3 Market Forecast
- 11.3 Japan
  - 11.3.1 Market Performance
  - 11.3.2 Key Players and Biosimilars
  - 11.3.3 Market Forecast
- 11.4 India
  - 11.4.1 Current Market Trends
  - 11.4.2 Key Players and Biosimilars
  - 11.4.3 Market Forecast
- 11.5 South Korea
  - 11.5.1 Current Market Trends
  - 11.5.2 Key Players and Biosimilars
  - 11.5.3 Market Forecast
- 11.6 Rest of the World
  - 11.6.1 Current Market Trends
  - 11.6.2 Market Forecast

## **12 REQUIREMENTS FOR SETTING UP A BIOSIMILAR MANUFACTURING PLANT**

- 12.1 Manufacturing Process
- 12.2 Raw Material Requirements
- 12.3 Raw Material Pictures
- 12.4 Land and Construction Requirements
- 12.5 Machinery and Infrastructure Requirements
- 12.6 Machinery Pictures
- 12.7 Plant Layout
- 12.8 Packaging Requirements
- 12.9 Utility Requirements
- 12.10 Manpower Requirements

## **13 COMPETITIVE LANDSCAPE**

- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
  - 13.3.1 Novartis
  - 13.3.2 Pfizer
  - 13.3.3 Teva
  - 13.3.4 Celltrion
  - 13.3.5 Merck & Co
  - 13.3.6 Samsung Bioepis
  - 13.3.7 Eli Lilly
  - 13.3.8 Biocon
  - 13.3.9 Amgen
  - 13.3.10 Dr. Reddy's Laboratories
  - 13.3.11 Boehringer Ingelheim



## List Of Figures

### LIST OF FIGURES

- Figure 1: Global Biosimilars Market: Sales Value (in Million US\$), 2012-2017
- Figure 2: Global: Biosimilars Market: Breakup by Molecule (in %), 2017
- Figure 3: Global: Biosimilars Market: Breakup by Manufacturer (in %), 2017
- Figure 4: Global Biosimilar Market: Breakup by Indication (in %), 2017
- Figure 5: Global Biosimilar Market: Breakup by Region (in %), 2017
- Figure 6: Global: Biosimilars Market Forecast: Sales Value (in Million US\$), 2018-2023
- Figure 7: Global Biosimilars Industry: SWOT Analysis
- Figure 8: Global: Biosimilars Market: Value Chain Analysis
- Figure 9: Global: Biosimilars Industry: Porter's Five Forces Analysis
- Figure 10: Global: Biosimilar Market: Average Price Trend of Inflectra
- Figure 11: Global: Biosimilar Market: Average Price Trend of Zarxio
- Figure 12: Biosimilars Industry: Breakup of Profit Margins at Various Level of the Value Chain
- Figure 13: Rituximab: Biosimilars Market: Sales Value (in Million US\$), 2016 & 2017
- Figure 14: Infliximab: Biosimilars Market: Sales Value (in Million US\$), 2015 - 2017
- Figure 15: Insulin Glargine: Biosimilars Market: Sales Value (in Million US\$), 2016 & 2017
- Figure 16: Epoetin Alfa: Biosimilars Market: Sales Value (in Million US\$), 2012 - 2017
- Figure 17 Filgrastim: Biosimilars Market: Sales Value (in Million US\$), 2012 - 2017
- Figure 18: Somatropin: Biosimilars Market: Sales Value (in Million US\$), 2012 - 2017
- Figure 19: Etanercept: Biosimilars Market: Sales Value (in Million US\$), 2016 & 2017
- Figure 20: Follitropin Alfa: Biosimilars Market: Sales Value (in Million US\$), 2015 – 2017
- Figure 21: In-House Manufacturing: Biosimilars Market: Sales Value (in Million US\$), 2012-2017
- Figure 22: In-House Manufacturing: Biosimilars Market Forecast: Sales Value (in Million US\$), 2018-2023
- Figure 23: Contract Manufacturing: Biosimilars Market: Sales Value (in Million US\$), 2012-2017
- Figure 24: Contract Manufacturing: Biosimilars Market Forecast: Sales Value (in Million US\$), 2018-2023
- Figure 25: Global: Biosimilar Market Forecast (Autoimmune Diseases): Sales Value (in Million US\$), 2018-2023
- Figure 26: Global: Biosimilar Market Forecast (Blood Disorders): Sales Value (in Million US\$), 2018-2023
- Figure 27: Global: Biosimilar Market Forecast (Diabetes): Sales Value (in Million US\$),

2018-2023

Figure 28: Global: Biosimilar Market Forecast (Oncology): Sales Value (in Million US\$), 2018-2023

Figure 29: Global: Biosimilar Market Forecast (Growth Deficiency): Sales Value (in Million US\$), 2018-2023

Figure 30: Global: Biosimilar Market Forecast (InFertility): Sales Value (in Million US\$), 2018-2023

Figure 31: Europe: Biosimilars Market: Sales Value (in Million US\$), 2010-2017

Figure 32: Europe: Biosimilars Market: Breakup by Country (in %), 2017

Figure 33: Europe: Biosimilars Market Forecast: Sales Value (in Million US\$), 2018-2023

Figure 34: Italy: Biosimilars Market: Sales Value (in Million US\$), 2010-2017

Figure 35: Italy: Biosimilars Market Forecast: Sales Value (in Million US\$), 2018-2023

Figure 36: Germany: Biosimilars Market: Sales Value (in Million US\$), 2010-2017

Figure 37: Germany: Biosimilars Market Forecast: Sales Value (in Million US\$), 2018-2023

Figure 38: France: Biosimilars Market: Sales Value (in Million US\$), 2010-2017

Figure 39: France: Biosimilars Market Forecast: Sales Value (in Million US\$), 2018-2023

Figure 40: United Kingdom: Biosimilars Market: Sales Value (in Million US\$), 2010-2017

Figure 41: United Kingdom: Biosimilars Market Forecast: Sales Value (in Million US\$), 2018-2023

Figure 42: Spain: Biosimilars Market: Sales Value (in Million US\$), 2010-2017

Figure 43: Spain: Biosimilars Market Forecast: Sales Value (in Million US\$), 2018-2023

Figure 44: Rest of Europe: Biosimilars Market: Sales Value (in Million US\$), 2010-2017

Figure 45: Rest of Europe: Biosimilars Market Forecast: Sales Value (in Million US\$), 2018-2023

Figure 46: United States: Biosimilars Market: Sales Value (in Million US\$), 2015-2017

Figure 47: United States: Biosimilars Market Forecast: Sales Value (in Million US\$), 2018-2023

Figure 48: Japan: Biosimilars Market: Sales Value (in Million US\$), 2012-2017

Figure 49: Japan: Biosimilars Market Forecast: Sales Value (in Million US\$), 2018-2023

Figure 50: India: Biosimilars Market: Sales Value (in Million US\$), 2012-2017

Figure 51: India: Biosimilars Market Forecast: Sales Value (in Million US\$), 2018-2023

Figure 52: South Korea: Biosimilars Market: Sales Value (in Million US\$), 2012-2017

Figure 53: South Korea: Biosimilars Market Forecast: Sales Value (in Million US\$), 2018-2023

Figure 54: Others: Biosimilars Market: Sales Value (in Million US\$), 2012-2017

Figure 55: Others: Biosimilars Market Forecast: Sales Value (in Million US\$), 2018-2023

Figure 56: Biosimilar Manufacturing: Detailed Process Flow

Figure 57: Biosimilar Manufacturing Plant: Raw Materials Requirement

Figure 58: Biosimilar Manufacturing Process: Conversion Rates of Products

Figure 59: Biosimilar Manufacturing Plant: Machinery Costs (in US\$)

Figure 60: Biosimilar Manufacturing Plant: Primary Packaging

Figure 61: Biosimilar Manufacturing Plant: Secondary Packaging

Figure 62: Biosimilar Manufacturing Plant: Tertiary Packaging

## List Of Tables

### LIST OF TABLES

Table 1: Global: Sales and Patent Expiry of Blockbuster Biological Drugs (in Million US\$), 2017

Table 2: Global: Biosimilars Market: Biosimilars Vs Innovators Drug Development

Table 3: Global: Biosimilars Market: Biosimilars Vs Biologics Manufacturing

Table 4: Global: Biosimilars market: Key Industry Highlights, 2017 and 2023

Table 5: US: Biosimilars Market: Patent Landscape

Table 6: Europe: Biosimilars Market: Patent Landscape

Table 7: Japan: Biosimilars Market: Patent Landscape

Table 8: Global: Biosimilars Market: Price Comparison Between Biosimilar and Originator Drugs

Table 9: Global: Biosimilars Market: Breakup by Molecule (in Million US\$), 2012-2017

Table 10: Global: Rituximab: Brand & Biosimilars Market Overview

Table 11: Global: Infliximab: Brand & Biosimilars Market Overview

Table 12: Global: Insulin Glargine: Brand & Biosimilars Market Overview

Table 13: Global: Epoetin Alfa: Brand & Biosimilars Market Overview

Table 14: Global: Filgrastim: Brand & Biosimilars Market Overview

Table 15: Global: Somatropin: Brand & Biosimilars Market Overview

Table 16: Global: Etanercept: Brand & Biosimilars Market Overview

Table 17: Global: Follitropin Alfa: Brand & Biosimilars Market Overview

Table 18: Global: Biosimilars Market Forecast: Breakup by Manufacturing Type (in Million US\$), 2018-2023

Table 19: Global: Biosimilars Market Forecast: Breakup by Indication (in Million US\$), 2018-2023

Table 20: Global: Biosimilars Market Forecast: Breakup by Region (in Million US\$), 2018-2023

Table 21: Europe: Biosimilars Market: Key Players and Biosimilars

Table 22: Italy: Biosimilars Market: Key Players and Biosimilars

Table 23: Germany: Biosimilars Market: Key Players and Biosimilars

Table 24: France: Biosimilars Market: Key Players and Biosimilars

Table 25: United Kingdom: Biosimilars Market: Key Players and Biosimilars

Table 26: Spain: Biosimilars Market: Key Players and Biosimilars

Table 27: United States: Biosimilar Market: Key Players and Biosimilar

Table 28: United States: Biosimilars Market: Launch of Expected Biosimilar

Table 29: Japan: Biosimilars Market: Key Players and Biosimilars

Table 30: India: Biosimilars Market: Key Players and Biosimilars

Table 31: South Korea: Biosimilars Market: Key Players and Biosimilar

Table 32: Biosimilar Manufacturing Plant: Manpower Requirements

Table 33: Biosimilar Market: Competitive Structure

Table 34: Global: Biosimilar Market: Key Players

## I would like to order

Product name: Biosimilar Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023

Product link: <https://marketpublishers.com/r/B8783BED1A1EN.html>

Price: US\$ 1,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B8783BED1A1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

